Abstract
Gene expression causally contributes to phenotypic variability. However, since tissue-specific gene expression is difficult to measure at scale, inferring phenotypic risk for individuals using expression profiles can be difficult. We statistically imputed tissue-specific gene expression for 486,452 UK Biobank participants and demonstrated its applications using rich phenotypic data in the biorepository. We performed joint analysis of transcriptome-wide association studies (TWAS) and colocalization for six traits to prioritize tissue-gene pairs for therapeutics development. Using genes identified in TWAS, we constructed imputed transcriptome risk scores and showed their predictive utility even when conditioning on genome-wide polygenic risk scores. A phenome-wide association analysis for established therapeutic targets in whole blood recapitulated known biology and prioritized repurposing potentials supported by previous literature. Our study provides evidence supporting the utility of individual-level imputed transcriptomes for discovering novel gene-tissue-phenotype trios, expression-based phenotypic risk prediction, and identifying individuals with therapeutically targetable predisposition to disease.
Competing Interest Statement
S.A.L. is a full-time employee of Novartis Institutes of BioMedical Research as of July 18, 2022. S.A.L. previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae. P.T.E. has received sponsored research support from Bayer AG and IBM Health, and he has consulted for Bayer AG, Novartis and MyoKardia.
Funding Statement
S.A.L. previously received support from NIH grants R01HL139731 and R01HL157635, and American Heart Association 18SFRN34250007 during this project. P.T.E. is supported by grants from the National Institutes of Health (1RO1HL092577, 1R01HL157635, 1R01HL157635), from the American Heart Association (18SFRN34110082), and from the European Union (MAESTRIA 965286). S.J.J. is supported by an Amsterdam UMC doctoral fellowship, and a Dutch Heart Foundation (Nederlandse Hartstichting) grant. S.H.C. was previously supported by the NHLBI BioData Catalyst Fellows program. J.T.R. was supported by a research fellowship from the Sigrid Juselius Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of UK Biobank data (under application number 17488) for the current study was approved by the Mass General Brigham (MGB) Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access to individual-level genetic and phenotypic data in the UK Biobank (UKB) is available to researchers through application on the UKB website (https://www.ukbiobank.ac.uk). Use of UKB data in the current study was performed under application number 17488.
